MoneyPig Trading

$HIMS: From "Gray Area" to "Global Powerhouse" The game just changed for Hims & Hers ($HIMS). Today’s settlement with Novo Nordisk isn’t just a legal win—it’s a massive fundamental re-rating. 🤝 Official NVO Partner: HIMS is now a legit distribution arm for branded Wegovy & Ozempic. 📈 Short Squeeze Fuel: 35%+ Short Interest is getting incinerated as we speak. 🏦 Valuation: Even at $22, it’s trading at <1.7x P/S on 2026 sales. Ridiculously cheap for a one-stop health shop Price Targets: 🎯 Short-term (May 2026): $28 - $32 (Gap fill + Squeeze) 🎯 Long-term (2030): $44+ (Global expansion & platform dominance) Not investment advice. Please invest at your own risks.

The UAE is expected to deplete its interceptor missile supply within a week at the current pace of launches, while Qatar could run out in four days; both nations are urgently pursuing additional military assistance from the United States, according to Bloomberg Watch drone stocks $KTOS $RCAT $ONDS $AVAV

Drone stocks $RCAT short interest 18%, days to cover 4.2 days $ONDS short interest 33%. days to cover 7.5 days Drone Dominance: Pentagon to order 30,000 one-way drones in ‘next few days’ - The DoD is about to choose the winners from its "Gauntlet" unmanned exercise and provide successful systems to military units "over the next five months," a DoD official said => A massive short squeeze might be on the way Not investment advice. we long both stocks $AVAV $KTOS $LMT $RTX

$AQST PDUFA 1/31/26 update: Based on tje poll (149 votes), ~52% expect a fixable CRL, vs ~36% approval (full or limited) If it’s a manufacturing/CMC-related CRL, the market may initially overreact & push AQST toward ~$2.5 on forced selling — even though this would likely be resubmittable in ~3–6 months. Historically, fixable CRLs = short-term pain, potential medium-term opportunity ($5~$6+/share) once FDA timelines are clarified $XBI $IWM $SPRY